McMaster University

McMaster University

Faculty of
Health Sciences

McMaster researcher receives $1.2 million to study treatment for a hard-to-treat cancer

Published: February 28, 2013
Anand Swaminath
Dr. Anand Swaminath, associate professor, Department of Oncology

A new type of radiation therapy could potentially change the standard of care for people with inoperable early-stage lung cancer.

The Canadian Cancer Society has awarded a $1.2 million Impact Grant to Dr. Anand Swaminath, an associate professor of oncology at McMaster University and a radiation oncologist at Juravinski Cancer Centre, to lead a Canadian clinical trial comparing two different types of radiation therapy for lung cancer.

Stereotactic radiation uses advanced imaging techniques to deliver extremely precise high doses of radiation in fewer treatments, while conventional radiation delivers lower doses in more frequent treatments. The effectiveness of these two radiation therapies in treating lung cancers has never been compared in a large clinical trial.

The clinical trial will look at the effectiveness of each type of radiation in shrinking tumours as well as overall survival, severity of side effects and quality of life for patients.

"If stereotactic radiation is found to be more effective than conventional therapy, with fewer side effects and lower healthcare costs, this type of radiation could become the standard of care for inoperable early-stage lung cancer across Canada and internationally," Swaminath said.

Swaminath’s grant is one of 11 new Impact Grants awarded by the Canadian Cancer Society for a total value of more than $13 million. This new funding program is designed to provide a mechanism for scientists to adopt innovations and accelerate the application of new knowledge to address problems in cancer research.

Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0